{
  "docId": "019dd923-5f69-752d-a9b8-7335d4e4bbbd",
  "docSlug": "UazyKuUCi7yVVPL3wJds",
  "documentTitle": "See the pitch deck that Compass Pathways used to raise $80 million and fuel its rise into one of the world's biggest psychedelics companies",
  "authorId": "Pitchdecks",
  "authorName": "Compass Pathways",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "strategy_consulting",
  "sourceTypeLabel": "Strategy consulting",
  "presentationDate": null,
  "orientation": "landscape",
  "aspectRatio": 1.333,
  "pageNumber": 11,
  "pageCount": 28,
  "prevPage": 10,
  "nextPage": 12,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 12,
  "notes": "The slide uses a timeline-based layout to present clinical trial results alongside corresponding data charts.",
  "elementsJson": [
    "action_title",
    "timeline_visual",
    "line_chart",
    "callout_box",
    "footnote"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-5f69-752d-a9b8-7335d4e4bbbd/11",
  "deckHref": "/decks/019dd923-5f69-752d-a9b8-7335d4e4bbbd",
  "deckJsonHref": "/decks/019dd923-5f69-752d-a9b8-7335d4e4bbbd.json",
  "deckAnchorHref": "/decks/019dd923-5f69-752d-a9b8-7335d4e4bbbd#slide-11",
  "components": [
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.8
      },
      "kind": "callout",
      "text": "Positive signals from early-stage trials present commercial opportunity for treatment-resistant depression, according to health care regulators",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "97c7b82a-26e0-424f-a609-1cffcf399e9d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.7,
        "w": 0.15,
        "x": 0.8,
        "y": 0.15
      },
      "kind": "chart",
      "text": "Clinical trial outcome charts",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d771bb94-6f64-4341-bbd5-d7cfd934188c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.7,
        "w": 0.7,
        "x": 0.05,
        "y": 0.15
      },
      "kind": "diagram",
      "text": "Timeline of clinical trials from 2011 to 2016",
      "attrs": null,
      "subkind": "timeline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a61c2bd8-38a2-4b5f-a019-d03bcc35c846",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.7,
        "x": 0.05,
        "y": 0.9
      },
      "kind": "disclaimer",
      "text": "* BDI = Beck Depression Inventory; QIDS = Quick Inventory of Depressive Symptoms; STAI = State-Trait Anxiety Inventory. 1. Detailed outcomes in scientific package 2. Based on data from 12 patients (different end points measured)",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fa640378-93c6-4f7c-959f-f2f0f3edd742",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "metric",
      "text": "Anti-depressant response rate: 92%",
      "attrs": null,
      "subkind": "primary",
      "toolName": "Quantification",
      "toolSlug": "quantification",
      "confidence": null,
      "componentId": "019dd952-a290-75b0-a217-abcbdd556d20",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.03
      },
      "kind": "title",
      "text": "Clinical Signals: Psilocybin therapy with immediate, significant, and sustained reduction in treatment-resistant depression & other illnesses",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0bb5ea1b-445f-4224-a424-25933dba4b65",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "timeline",
      "slug": null,
      "matchId": "f502a087-0cf5-4a6b-b1f8-b51971877279",
      "evidence": "Chronological presentation of clinical trials",
      "confidence": 1
    }
  ],
  "arcBeats": [
    {
      "to": 17,
      "from": 10,
      "beatId": "1b24f627-5397-46d5-a3ed-637425948073",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "Slides 10 through 17 present psilocybin therapy as a solution, detailing its value proposition, development program, and market potential.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}